|
Test
|
Sensitivity (%)
|
Specificity (%)
|
ROC AUC
|
|---|
|
HCC versus LC
| | | |
|
4-ion UPLC-MS model
|
78.1
|
63.6
|
0.819b,c
|
|
AFP20 ng/mL
|
37.5
|
93.3
|
0.779d
|
|
AFP200 ng/mL
|
18.8
|
100.0
|
0.779d
|
|
4-ion UPLC-MS model
|
75.0
|
83.3
|
0.856
|
|
+ AFP20 ng/mL
a
|
|
HCC versus CHB
| | | |
|
4-ion UPLC-MS model
|
93.8
|
80.0
|
0.864e,f
|
|
2-ion UPLC-MS model
|
96.9
|
80.0
|
0.933g
|
|
RT 3.40_773.5478 n
|
100.0
|
100.0
|
1.000
|
|
RT 1.87_534.3902 m/z
|
100.0
|
100.0
|
1.000
|
|
RT 6.25_369.3538 m/z
|
100.0
|
100.0
|
1.000
|
|
RT 3.45_822.5670 m/z
|
100.0
|
100.0
|
1.000
|
|
RT 3.59_770.5691 m/z
|
100.0
|
100.0
|
1.000
|
|
RT 4.23_851.6090 m/z
|
100.0
|
100.0
|
1.000
|
|
RT 3.99_826.5920 m/z
|
100.0
|
100.0
|
1.000
|
|
HCC versus HS
| | | |
|
4-ion UPLC-MS model
|
90.6
|
88.2
|
0.946
|
-
ROC receiver operating characteristic, AUC area under the curve, HCC hepatocellular carcinoma, LC liver cirrhosis, AFP alpha-fetoprotein, UPLC ultra performance liquid chromatography, MS mass spectrometry, CHB chronic hepatitis B, RT retention time, n neutral, m/z mass to charge ratio, HS healthy subjects. aCombination of the 4-ion UPLC-MS model and AFP20 ng/mL.
bCompared with AFP20 ng/mL or AFP200 ng/mL, P = 0.616. cCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.610. dCompared with 4-ion UPLC-MS model + AFP20 ng/mL, P = 0.312. eCompared with 2-ion UPLC-MS model, P = 0.241. fCompared with individual ions, P = 0.047. gCompared with individual ions, P = 0.005
